Remsima®SC
-
Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada.
- Product Name : Remsima®SC
- INN : Infliximab
- Indications : Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
- Drug Approval Status : Korea, Europe, Canada
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
